Medexus Pharmaceutical (OTCMKTS:MEDXF): Trecondyv Now Available Commercially in Canada
Trecondyv or treosulfan will now be made available by Medexus Pharmaceutical (OTCMKTS:MEDXF) in Canada. Till date, it had only been distributed under the Health Canada Special Access Program. It is a bifunctional alkylating agent that is used as part of a conditioning treatment for patients undergoing allogeneic hematopoietic stem cell transplantation. It can be commercially sold in Canada for adult patients suffering from Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS). It will also be administered in pediatric patients over a year old with AML or MDS.
Vice President of Specialty Markets at Medexus, Kerry Bakewell, is hopeful this development will help hundreds of patients who urgently require this treatment. This product could go on to become the standard of care in the country as it has excellent event-free and overall survival data, especially among at-risk groups. So far, there has been positive feedback from the medical community in Canada.
This treatment has been in use under the Special Access Program, with tutelage of Dr. Ivan Pasic, Medical Oncologist, Princess Margaret Cancer Centre, spearheading it. Dr. Pasic believes that treosulfan works wonders in providing a technique of transplantation safely, without considerably increasing relapse risk. Patients under this program (with MDS), who are ineligible to receive standard myeloablative conditioning because of their age and/or co-morbidities, are being given treosulfan.
